OptionsHouse

Options Trading News

April 5, 2011  Tue 7:33 AM CT

CBST: SEE CHART GET CHAIN FIND STRATEGIES
Deal to Help Cubist Grow Business

CBSTThe drug maker settled a patent dispute with Teva Pharmaceutical Industries over its Cubicin antibiotic. The agreement delays TEVA's production of the drug as a generic by six months and will make it easier for Cubist to market the drug, its only product. CBST is up 15 percent in the premarket.


SemiLEDs Reports Surprise Loss

The maker of light-emitting diodes reported a loss of $0.03, missing the $0.08 profit forecast. Revenue and guidance also missed the mark, and LEDS is down 23 percent before the bell.


Questcor Sees Revenue Ahead of Consensus

The pharmaceuticals company said paid prescriptions for its Acthar Gel to treat multiple sclerosis more than doubled. The company estimated it had first-quarter sale of $48.6 million, while analysts had expected $33.60 million. QCOR climbs 14 percent before the bell.


(Chart courtesy of tradeMONSTER)
Share this article with your friends


Invest Like a Monster - San Diego: June 26-27

TRADING WEEKLY OPTIONS

The fastest money in the market
View full report »

Premium Services

Archived Webinar

Education & Strategy

Long synthetic call

Long and short Synthetic stock are two of the six basic synthetic positions that exist. Number three on our list is the Synthetic Long Call...

View more education articles »